Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis

Antiviral Therapy

Volumn 7, Issue 3, 2002, Pages 195-197

  García, Felipe ^a   Plana, Montserrat ^a   Mestre, Gabriel ^a   Cruceta, Anna ^a   Martinez, Esteban ^a   Miró, José M ^a   Mallolas, Josep ^a   Tuset, Montserrat ^a   Pumarola, Tomas ^a   Gallart, Teresa ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LIVER ENZYME; MITOGENIC AGENT; NELFINAVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; EXPOSURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; IMMUNOMODULATION; LIPID BLOOD LEVEL; LYMPHOCYTE PROLIFERATION; MALE; METABOLISM; PRIORITY JOURNAL; PROPHYLAXIS; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 0036768695     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Plana M, Garcia F, Gallart MT, Miro JM & Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet 1998; 352:1194-1195.
2. Parkin JM, Murphy M, Anderson J, El Gadi S, Forster G & Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000; 355:722-723.
3. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures. World-wide 1997-2000. MMWR Morbidity and Mortality Weekly Report 2001; 49:1153-1156.
4. Italian Registry of Antiretoviral post-exposure prophylaxis. Effect of short-course of antiretroviral agents on serum triglycerides of healthy individuals. AIDS 2000; 14:2407-2408.
5. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C & Brunzell JD. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14:51-57.
6. Puro V & Ippolito G. Effect of antiretroviral agents on Tlyphocyte subset counts in healthy HIV-negative individuals. Journal of Acquired Immune Deficiency Syndromes 2000; 24:440-443.
7. Milazzo L, Vaira LM, Cremoni L. CD4 lymphocyte count variations in HIV-negative subjects treated with zidovudine. AIDS 1996; 10:1444-1445.
8. de Martino M, Galli L, Chiarelli F, Rossi ME & Vierucci A. Do nucleoside analogues directly influence T lymphocyte subset counts? The pediatric model. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998; 18:391-393.
9. Barker E, Kahn J, Fujimura S & Levy JA. Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals. AIDS 1998; 12:1117-1118.
10. Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC & Reitz MS. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. Journal of Human Virology 1999; 2:261-269.
11. Sloand E, Kumar PN, Chaudhuri A, Weichold FF & Young NS. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999; 94:1021-1027.
12. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J & Badley AD. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001; 98:1078-1085.
13. Levy JA, Ramachandran B, Barker E, Guthrie J, Elbeik T & Coffin JM. Plasma viral load, CD4+ cell counts, and HIV-1 production by cells. Science 1996; 271:670-671.
14. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P & Leibowitch J. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
15. Plana M, García F, Gallart MT, Tortajada C, Soriano A, Palou E, Maleno MJ, Barcelo JJ, Vidal C, Cruceta A, Miro JM & Gatell JM. Immunological benefits of antiretroviral therapy in very early stages of asymtomatic chronic HIV-1 infection. AIDS 2000; 14:1921-1933.